Roche Holding AG has more than five medicines that it could combine with weight-loss drugs, Chief Executive Officer Thomas ...

The pharma company said it believes there’s plenty of room for multiple industry players in the obesity drug market.

Roche said on Monday that three early-stage obesity and diabetes drug candidates from its acquisition of Carmot Therapeutics ...

Roche argued that its obesity medications would prove to have advantages over its rivals’ — and that the demand for weight ...

Irishman congratulates Slovenian as first man in 37 years to win the World Championships, Giro d'Italia and Tour de France ...

Roche Holding AG is aiming to deliver 20 new medicines to address diseases that rank among the biggest burdens to society ...

Roche is spending $850 million upfront to buy Regor Pharmaceuticals’ suite of next-generation CDK inhibitors as it doubles ...

In a report released today, Eric Le Berrigaud from Stifel Nicolaus maintained a Hold rating on Roche Holding AG (RHHVF – Research ...

The Temperature-Activated Generation of Signal (TAGS) technology was developed by Roche for its high-throughput PCR-based instruments.

Roche said it plans to focus on five key therapeutic areas as part of its new pharma strategy through 2030. The company will prioritize work in the areas of neurology, oncology and hematology, ...

(RTTNews) - Swiss drug major Roche Group (RHHBY), at its Pharma Day 2024, said it expects sales momentum to continue into 2025, with strong growth by both divisions of Pharma and Diagnostics. The ...

The the Swiss drugmaker will face off in the obesity area with leaders Novo Nordisk A/S and Indianapolis-based Eli Lilly and ...